tafamidis Products (Vyndaqel®, Vyndamax™)

Policy # 00694
Original Effective Date: 10/09/2019
Current Effective Date: 11/08/2021

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the “Company”), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Note: Treatment of polyneuropathy of hereditary transthyretin amyloidosis is addressed separately in medical policy 00670.

When Services May Be Eligible for Coverage
Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member’s contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider tafamidis meglumine (Vyndaqel®)† or tafamidis (Vyndamax™)‡ for the treatment of the cardiomyopathy of transthyretin-mediated amyloidosis (ATTR) to be eligible for coverage.**

Patient Selection Criteria
Coverage eligibility will be considered for tafamidis meglumine (Vyndaqel) or tafamidis (Vyndamax) when the following criteria are met:

- Initial:
  - Patient has a diagnosis of cardiomyopathy of wild-type or hereditary transthyretin amyloidosis (ATTR); AND
  - Diagnosis is confirmed by ONE of the following:
    - A technetium pyrophosphate scan (i.e. nuclear scintigraphy); OR
    - Amyloid deposits identified on cardiac biopsy; AND
  - Patient is greater than or equal to 18 years of age; AND
  - Diagnostic cardiac imaging (e.g., echocardiogram, cardiac magnetic resonance imaging) has demonstrated cardiac involvement (e.g., increased thickness of the ventricular wall or interventricular septum); AND
  - Patient has New York Heart Association class I, II, or III heart failure; AND

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
tafamidis Products (Vyndaqel®, Vyndamax™)

Policy # 00694
Original Effective Date: 10/09/2019
Current Effective Date: 11/08/2021

(Note: This criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)
- Other forms of amyloidosis (e.g. light chain amyloidosis) have been ruled out; AND
  (Note: This criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)
- Patient has NOT received a liver transplant; AND
  (Note: This criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)
- Requested drug will NOT be used in combination with patisiran (Onpattro™)† or inotersen (Tegsedi™)†.

- Continuation:
  - Patient has received an initial authorization for the requested drug; AND
  - Patient does NOT have New York Heart Association class IV heart failure; AND
    (Note: This criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)
  - Patient has NOT received a liver transplant; AND
    (Note: This criterion is an additional Company requirement for coverage eligibility and will be denied as not medically necessary** if not met.)
  - Requested drug will NOT be used in combination with patisiran (Onpattro™) or inotersen (Tegsedi™).

** When Services Are Considered Not Medically Necessary**
Based on review of available data, the Company considers the use of tafamidis meglumine (Vyndaqel) or tafamidis (Vyndamax) when the patient has New York Heart Association class IV heart failure, has another form of amyloidosis, or has received a liver transplant to be **not medically necessary.**

When Services Are Considered Investigational
Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.
Based on review of available data, the Company considers the use of tafamidis meglumine (Vyndaqel) or tafamidis (Vyndamax) when the patient selection criteria are not met (except for those denoted above as not medically necessary**) to be investigational.*

**Background/Overview**
Vyndaqel and Vyndamax are two formulations of the tetramer stabilizer, tafamidis, and are each indicated to reduce cardiovascular mortality and cardiovascular-related hospitalization in adults with cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (ATTR-CM).

Vyndaqel was the first of these products to launch and should be dosed as 80 mg (four 20 mg capsules) once daily. Vyndamax is an alternative formulation of tafamidis that was developed to allow for ease of dosing. The dose of Vyndamax is 1 capsule (61 mg) daily, which is bioequivalent to 80 mg of Vyndaqel. These drugs are the first products approved in the United States for the treatment of the cardiomyopathy associated with hereditary or wild-type transthyretin mediated amyloidosis (ATTR). However, Vyndaqel is approved in Europe for the treatment of the polyneuropathy of ATTR, an indication that the FDA declined to approve in 2012. Clinical trials of Vyndaqel for cardiomyopathy excluded patients with a history of liver transplantation, New York Heart Association (NYHA) class IV heart failure, and other forms of amyloidosis (e.g., light-chain amyloidosis).

The TTR protein is primarily produced in the liver and circulates as a stable tetramer, transporting vitamin A and thyroxine throughout the body. With aging or in the setting of a mutation of the TTR gene, the stability of the TTR tetramer is altered, resulting in misfolding of the TTR protein. This leads to accumulation of amyloid in organs and tissues, causing symptoms based on the organ(s) involved. The most prominent symptoms are often those of cardiomyopathy or polyneuropathy (ATTR-CM or ATTR-PN). In ATTR-CM, amyloid deposits in cardiac tissue cause a weakening and/or stiffening of the heart. Although the clinical course varies, patients typically exhibit heart failure with preserved ejection fraction, but some patients may present with right-sided heart failure, atrial fibrillation, bundle branch block and complete heart block, angina, or cardiogenic shock. In ATTR-PN, neurologic symptoms include severe sensorimotor disturbances (loss of sensation, pain, muscle weakness, and loss of ambulation) and autonomic dysfunction resulting in orthostatic hypotension, diarrhea, impotence, and bladder disturbances. Patients may also present with a mixed phenotype and exhibit signs of both neuropathy and cardiomyopathy. This condition is progressive, debilitating, and life-threatening and may go unrecognized and result in late-stage diagnosis.
Management of cardiomyopathy associated with ATTR includes sodium restriction and diuretic therapy. The combination of loop diuretics and an aldosterone antagonist is most effective. Although there are no current nationally recognized guidelines for the treatment of ATTR-CM, the Cleveland Clinic amyloidosis center published an update on the diagnosis and treatment of cardiac amyloidosis in 2017, prior to the approval of Vyndaqel in the United States. Treatment should focus on management of cardiac symptoms and treating the underlying disease. Liver transplantation is a potential treatment for the hereditary mutant variant of TTR, but not for wild-type disease. Heart transplantation is a treatment option for patients with both wild-type and hereditary variants of ATTR-CM. Although limited data are available, the following 3 pharmacologic classes were discussed for treatment or future treatment of the underlying disease process: 1) agents that block TTR synthesis (e.g. Tegsedi or Onpattro), 2) therapies that stabilize the TTR tetramer (e.g. Vyndaqel, diflunisal); and 3) agents that disrupt and clear the ATTR amyloid fibril (e.g. doxycycline). Currently, there is no evidence supporting the use of any of these products in combination with each other.

**FDA or Other Governmental Regulatory Approval**

U.S. Food and Drug Administration (FDA)

Vyndaqel and Vyndamax were approved in May 2019 for the treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

**Rationale/Source**

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. FDA approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, Blue Cross and Blue Shield Association technology assessment program (TEC) and other non-affiliated technology evaluation centers, reference to federal regulations, other plan medical policies, and accredited national guidelines.

Efficacy of tafamidis was demonstrated in a multicenter, international, randomized, double-blind, placebo-controlled study in 441 patients with wild type or hereditary ATTR-CM. Patients were randomized in a 1:2:2 ratio to receive Vyndaqel 20 mg (n=88), Vyndaqel 80 mg (administered as four 20-mg Vyndaqel capsules) (n=176), or matching placebo (n=177) once daily for 30 months, in
tafamidis Products (Vyndaqel®, Vyndamax™)

Policy # 00694
Original Effective Date: 10/09/2019
Current Effective Date: 11/08/2021

addition to standard of care (e.g., diuretics). Treatment assignment was stratified by the presence or absence of a variant TTR genotype as well as baseline disease severity (New York Heart Association Class). Transplant patients were excluded from this study.

The primary analysis used a hierarchical combination applying the method of Finkelstein-Schoenfeld (F-S) to all-cause mortality and frequency of cardiovascular-related hospitalizations, which was defined as the number of times a subject was hospitalized for cardiovascular-related morbidity. The method compared each patient to every other patient within each stratum in a pairwise manner that proceeded in a hierarchical fashion using all-cause mortality followed by frequency of cardiovascular-related hospitalizations when patients could not be differentiated based on mortality. This analysis demonstrated a significant reduction (p=0.0006) in all-cause mortality and frequency of cardiovascular-related hospitalizations in the pooled Vyndaqel 20 mg and 80 mg groups versus placebo. In the pooled Vyndaqel group, 70.5% of subjects were alive at month 30 compared to 57.1% of subjects in the placebo group. In addition, those alive in the pooled Vyndaqel group had an average of 0.297 cardiovascular-related hospitalizations compared to 0.455 in the placebo group.

Efficacy and safety of Vyndamax are based on pharmacokinetic studies demonstrating equivalence of Vyndamax 61 mg to Vyndaqel 80 mg (administered as four 20 mg capsules).

References

Policy History
Original Effective Date: 10/09/2019
Current Effective Date: 11/08/2021
10/03/2019 Medical Policy Committee review
10/01/2020 Medical Policy Committee review
10/07/2020 Medical Policy Implementation Committee approval. No change to coverage.
10/07/2021 Medical Policy Committee review
10/13/2021 Medical Policy Implementation Committee approval. No change to coverage.

©2021 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.
tafamidis Products (Vyndaqel®, Vyndamax™)

Policy # 00694
Original Effective Date: 10/09/2019
Current Effective Date: 11/08/2021

Next Scheduled Review Date: 10/2022

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:
   A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
   B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
      1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
      2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
      3. Reference to federal regulations.

**Medically Necessary (or “Medical Necessity”) - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:
   A. In accordance with nationally accepted standards of medical practice;
   B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
   C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, “nationally accepted standards of medical practice” means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally
tafamidis Products (Vyndaqel®, Vyndamax™)

Policy # 00694
Original Effective Date: 10/09/2019
Current Effective Date: 11/08/2021

recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient’s health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.